Previous 10 | Next 10 |
Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativa Positive Phase IIa data reported with vilobelimab in pyoderma gangrenosum; data being presented as late-breaker oral presentation at AAD Annual Meeting Topline data in vil...
Summer Infant (SUMR) +29% on Q4 results. Imperial Petroleum (IMPP) +19%. Mullen Automotive (MULN) +19% featured by Yahoo Finance live. Indonesia Energy (INDO) +18%. F-star Therapeutics (FSTX) +16%. Enservco (ENSV) +16%. Aquestive Therapeutics (AQST) +16% receives FDA fast track...
JENA, Germany, March 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today reported that the Company has received a corrected advice letter from the U.S. Food a...
JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that final data from the Company’s Phase IIa open-label study with vilobel...
Gainers: Clover Health Investments (NASDAQ:CLOV) +18%. Monte Rosa Therapeutics (NASDAQ:GLUE) +12%. Sharecare (NASDAQ:SHCR) +10%. InflaRx (NASDAQ:IFRX) +9%. Sigilon Therapeutics (NASDAQ:SGTX) +9%. Losers: Atreca (NASDAQ:BCEL) -30%. Biophytis (NASDAQ:BPTS) -14%. Alpine Immun...
InflaRx (NASDAQ:IFRX) is pausing activities related to a phase 3 trial of vilobelimab for treating hidradenitis suppurativa as the company seeks clarity on advice received from the FDA related to the main goal of the study. The company noted that the FDA has not issued a clinical ho...
JENA, Germany, Feb. 28, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today reported that the Company has received an advice letter from the U.S. Food and Drug Ad...
The following slide deck was published by InflaRx N.V. in conjunction with this event. For further details see: InflaRx (IFRX) Presents At Annual SVB Leerink Global Health Conference
In vilobelimab and pembrolizumab combination arm, the three patients enrolled in the first dosing cohort have been treated for 36 days with no safety concerns Steering Committee unanimously voted to continue study as planned and open enrollment for second dosing cohort Enrollment ...
JENA, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the 11 th Annual SVB Leerink Healthcare Conference being held virtually ...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...